Other Health News Topics Human Papillomavirus (HPV)
EACS 2017: European AIDS Clinical Society Strengthens HPV Vaccination Advice
- Details
- Category: Human Papillomavirus (HPV)
- Published on Tuesday, 07 November 2017 00:00
- Written by Keith Alcorn
The European AIDS Clinical Society (EACS) has recommended human papillomavirus (HPV) vaccination for everyone living with HIV aged under 26 and all men who have sex with men up to the age of 40.
PAS 2017: Vaccine Reduces Human Papillomavirus Prevalence Among Young Women
- Details
- Category: HPV Vaccines
- Published on Tuesday, 16 May 2017 00:00
- Written by Liz Highleyman
The prevalence of human papillomavirus (HPV) types included in the most widely used vaccine has decreased among adolescent and young women in the U.S., with "herd immunity" extending to those who were not vaccinated themselves, according to study results presented at the Pediatric Academic Societies Meeting last week in San Francisco.
ICAAC 2014: Anal HPV Infection and Dysplasia Common in HIV+ Women and Gay Men
- Details
- Category: Human Papillomavirus (HPV)
- Published on Friday, 03 October 2014 00:00
- Written by Liz Highleyman
Anal infection with high-risk human papillomavirus (HPV) types was common among women with HIV in France, while a Spanish study found a low rate of pre-cancerous anal cell changes in HIV positive women compared with men who have sex with men, researchers reported at the recent 54th Interscience Conference on Antimicrobial Agents and Chemotherapy in Washington, DC.
Young Adolescents Need Only 2 Doses of Human Papillomavirus Vaccine, CDC Says
- Details
- Category: HPV Vaccines
- Published on Tuesday, 08 November 2016 00:00
- Written by Liz Highleyman
Adolescents age 11-14 years can receive 2 doses of the human papillomavirus (HPV) vaccine to prevent cancers caused by HPV, rather than the 3 doses previously recommended, according to the U.S. Centers for Disease Control and Prevention (CDC). This change is supported by a systematic review presented at the recent IDWeek meeting in New Orleans, which found that 2 vaccine doses were non-inferior to 3 doses for this age group.
AIDS 2014: Young People with HIV Respond Well to Human Papillomavirus Vaccine
- Details
- Category: HPV Vaccines
- Published on Tuesday, 29 July 2014 00:00
- Written by Liz Highleyman
The quadrivalent human papillomavirus (HPV) vaccine worked as well for teens and young adults with HIV as it did for their HIV negative counterparts, according to study findings presented the 20thInternational AIDS Conference last week in Melbourne.
Gardasil HPV Vaccine Reduces Occurrence of Genital Warts and Cervical Dysplasia
- Details
- Category: Human Papillomavirus (HPV)
- Published on Thursday, 30 June 2016 00:00
- Written by Liz Highleyman
Countries that widely use a quadrivalent human papillomavirus (HPV) vaccine have seen up to a 90% reduction in HPV infections and decreases in the incidence of genital warts and cervical cell abnormalities that can lead to cancer, according to an analysis of nearly 60 studies from 9 countries presented at the European Research Organization on Genital Infection and Neoplasia and published in the May 26 edition of Clinical Infectious Diseases.
Human Papillomavirus Vaccine Is Effective for Women with HIV
- Details
- Category: Women & HIV
- Published on Tuesday, 06 May 2014 00:00
- Written by Liz Highleyman
HIV positive women respond well to the Gardasil human papillomavirus (HPV) vaccine, offering them protection against cervical cancer, according to a study published in the April 14 electronic edition of Clinical Infectious Diseases. Related recent research found that both Gardasil and Cervarix are effective in people with HIV.
ASCO 2016: PD-1 Blocker Nivolumab Shows Promise for Advanced Anal Cancer
- Details
- Category: Anal & Cervical Cancer
- Published on Monday, 06 June 2016 00:00
- Written by MD Anderson Cancer Center
The checkpoint inhibitor nivolumab(Opdivo), a monoclonal antibody targeting the PD-1 receptor, demonstrated activity against metastatic anal cancer that in patients who did not respond to prior treatment, according to research presented at the American Society of Clinical Oncology (ASCO) annual meeting this week in Chicago. 70% of participants in this small study experienced complete or partial response or stabilized disease.
FDA Approves HPV DNA Test as Pap Smear Alternative for Cervical Cancer Screening
- Details
- Category: Human Papillomavirus (HPV)
- Published on Tuesday, 29 April 2014 00:00
- Written by FDA
The U.S. Food and Drug Administration (FDA) last week approved Roche Diagnostics' cobas human papillomavirus (HPV DNA test for initial screening for cervical cancer. The test detects high-risk or cancer-causing HPV types including HPV-16 and HPV-18. Women who test positive for high-risk HPV can then undergo further testing for pre-cancerous or malignant cell changes.
CDC Releases Updated Sexually Transmitted Disease Treatment Guidelines
- Details
- Category: Human Papillomavirus (HPV)
- Published on Thursday, 16 July 2015 00:00
- Written by HIVandHepatitis.com
In June the U.S. Centers for Disease Control and Prevention (CDC) published updates guidelines for the treatment of sexually transmitted diseases (STDs). The guidelines include information on more than 2 dozen different sexually transmitted infections, as well as STD complications such as pelvic inflammatory disease and cervical and anal cancer.
CROI 2014: Natural History of HIV-Related Anal Dysplasia [VIDEO]
- Details
- Category: Anal & Cervical Cancer
- Published on Tuesday, 11 March 2014 00:00
- Written by Gregory Fowler
The progression of anal dysplasia is highly variable in people with HIV, progressing in some and remaining stable or regressing in others, according to a retrospective analysis of nearly 3000 participants presented at the 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014) last week in Boston. Progression to invasive anal cancer, however, was uncommon.
Single Dose of Human Papillomavirus Vaccine May Prevent Most Cervical Cancer
- Details
- Category: HPV Vaccines
- Published on Wednesday, 17 June 2015 00:00
- Written by Liz Highleyman
Just 1 dose of the Cervarix human papillomavirus (HPV) vaccine was able to protect 85% of young women against cancer-causing HPV types 16 and 18, suggesting that it could prevent a majority of cervical cancer cases, including in settings were administration of the full 3-dose series is difficult, according to an analysis of data from 2 large trials published in the June 9 edition of Lancet Oncology.
Black Women More Likely to Carry Human Papillomavirus Strains Not Covered by Vaccines
- Details
- Category: HPV Vaccines
- Published on Wednesday, 30 October 2013 00:00
- Written by Duke University
African-American women with precancerous cervical abnormalities are about half as likely to have cancer-causing human papillomavirus (HPV) types 16 and 18, and more likely to have other types for which the Gardasil and Cervarix vaccines do not provide protection, according to a study presented at the American Association for Cancer Research International Conference on Frontiers in Cancer Prevention Research taking pace this week in Maryland.
CROI 2015: Screening May Miss Pre-cancerous Anal Lesions in Women with HIV
- Details
- Category: Human Papillomavirus (HPV)
- Published on Monday, 09 March 2015 00:00
- Written by Theo Smart
Existing algorithms to screen for anal cancer in women living with HIV could be missing many cases of anal high-grade squamous intraepithelial lesions (HSIL) -- abnormal tissue changes that may be a precursor to invasive anal cancer -- according to a study reported at the recent 2015 Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle.
EACS 2013: Ensuring Good Quality HIV Care in Europe: Where Can We Improve?
- Details
- Category: Cascade of Care
- Published on Monday, 21 October 2013 00:00
- Written by Keith Alcorn
Only 20% of people with HIV in Europe have fully suppressed viral load, compared to an estimated 24% in sub-Saharan Africa, despite much higher rates of HIV diagnosis in the European region, Professor Jens Lundgren of the University of Copenhagen told the 14th European AIDS Conference in Brussels on Saturday.
12. New Human Papillomavirus Vaccine Protects Against 9 Strains
- Details
- Category: Human Papillomavirus (HPV)
- Published on Monday, 12 January 2015 00:00
- Written by HIVandHepatitis.com
In December the U.S. Food and Drug Administration (FDA) approved a new "9-valent" human papillomavirus (HPV) vaccine from Merck that protects against more cancer-causing strains. The new Gardasil 9 vaccine is expected to prevent about 90% of cervical, anal, and genital cancers. The vaccine is approved for young women ages 9-26 and young men ages 9-15.
EACS 2013: Anal Cancer Screening May Be Appropriate for All Women with HIV
- Details
- Category: Cancer/Malignancies
- Published on Thursday, 17 October 2013 00:00
- Written by Keith Alcorn
Women living with HIV had a higher risk of anal pre-cancerous changes than cervical changes linked to human papillomavirus (HPV), French researchers reported at the 14th European AIDS Conference this week in Brussels. They suggested that all women with HIV ought to be screened routinely for pre-cancerous changes in the anal canal.
WHO Recommends 2-Dose Vaccine, HPV Screening for Cervical Cancer Prevention
- Details
- Category: Anal & Cervical Cancer
- Published on Tuesday, 09 December 2014 00:00
- Written by WHO
The World Health Organization (WHO) last week released new guidance for preventing and controlling cervical cancer, which causes more than 270,000 deaths annually worldwide. The guidelines call for girls to receive 2 rather than 3 doses of the human papillomavirus (HPV) vaccine and for women to be screened using less frequent HPV tests rather than Pap smears.
IDWeek 2013: HIV+ Young Women Have Adequate Response to Human Papillomavirus Vaccine
- Details
- Category: HPV Vaccines
- Published on Tuesday, 15 October 2013 00:00
- Written by Liz Highleyman
HIV positive girls did not respond as well to the quadrivalent human papillomavirus (HPV) vaccine as HIV negative girls of the same age, but they responded as well as HIV negative older women, probably giving them sufficient protection from infection, according to a late-breaker presentation at the recent IDWeek conference in San Francisco.
FDA Approves New Vaccine Effective Against 9 Types of Human Papillomavirus
- Details
- Category: Anal & Cervical Cancer
- Published on Tuesday, 09 December 2014 00:00
- Written by WHO
The U.S. Food and Drug Administration this week approved a new "9-valent" human papillomavirus (HPV) vaccine from Merck that protects against infection with more high-risk or cancer-causing strains. The new Gardasil 9 vaccine is expected to prevent about 90% of cervical, anal, and genital cancers. The vaccine is approved for young women ages 9-26 and young men ages 9-15.
IDWeek 2013: Low-income Girls Are Less Likely to Receive Full HPV Vaccine Series
- Details
- Category: HPV Vaccines
- Published on Friday, 04 October 2013 00:00
- Written by IDWeek 2013
Low-income adolescents are not as likely to start or finish the 3-shot human papillomavirus (HPV) vaccine series, which reduces the risk of cervical cancer. Cultural differences can help explain some of the reasons for this disparity and suggest targeted approaches for encouraging vaccination, researchers reported at Second IDWeek conference this week in San Francisco.
Web Design and Development by